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2003). The main findings were: 1) the evidence supporting the use of
PTCA prior to NCS as a strategy to lower the rate of perioperative
adverse cardiac outcomes is limited and inconclusive; moreover, the
largest reported study (2) showed serious adverse outcomes in patients
subjected to NCS within 90 days of PTCA; and 2) coronary stenting
performed shortly before NCS (especially during first two weeks) is
associated with increased perioperative morbidity and mortality rates.
Antithrombotic therapy following percutaneous coronary inter-
vention (PCI) in patients requiring NCS has to balance the risk of
stent thrombosis against the risk of surgical bleeding. Systemic
inflammatory and procoagulatory responses occur after PCI (5,6);
these may be amplified by major NCS (7), thus increasing the risk of
perioperative coronary thrombotic complications. Therefore, an anti-
thrombotic regimen effective in the nonsurgical setting may not be
effective to prevent stent thrombosis, but it may be sufficient to cause
major surgical bleeding. Until further data are available, NCS follow-
ing PCI should be deferred whenever possible for at least four weeks,
allowing the completion of currently recommended antiplatelet ther-
apy to prevent the thrombotic complications associated with PCI.
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REPLY
We thank Dr. Auer and colleagues for raising an important issue.
All patients in our study were enrolled between 1990 and 2000,
before drug-eluting stents (DESs) were available. Therefore, the
results of our study and any conclusions they permit should only be
applied to bare stents, and we explicitly stated that they should not
be applied to situations in which re-endothelialization is delayed,
such as brachytherapy.
Little is known about how patients ought to be managed prior
to noncardiac surgery in the DES era, an issue that has already
arisen many times at the Mayo Clinic. The answer may differ
depending on which DES is being considered (1). The two studies
cited, revealing that use of DESs delays endothelialization, were
both of paclitaxel-eluting stents, but the polymer, release mecha-
nisms, stent design, and, in the Farb study, the animal model
(rabbits) were too different to extrapolate to the TAXUS program.
With the slow-release formulation on the paclitaxel stent being
commercialized, approximately 10% of the paclitaxel is released by
10 days, whereas the remaining 90% remains in the polymer
indefinitely. The clinical significance of this is unclear. In contrast,
sirolimus has nearly entirely eluted from a Cypher stent within 30
to 45 days, essentially leaving a polymer-coated bare metal stent.
Animal models suggest that the sirolimus stent may not delay
re-endothelialization (2,3) but that the paclitaxel stent does (Dr.
R. S. Schwartz, personal communication, January 12, 2004).
However, based on the design of the pivotal clinical trials
leading to approval of these stents (and not on what is known
about the rate of re-endothelialization in humans), clopidogrel is
recommended for two to three months following placement of a
sirolimus-eluting stent and for six months following placement of
a paclitaxel-eluting stent. Accordingly, until the clinical outcomes
of large numbers of patients who received a DES and who did not
complete their assigned course of clopidogrel are analyzed, we
recommend the following. If a patient requires noncardiac surgery
within two months of percutaneous coronary intervention (PCI),
and the type of surgery (or surgeon) will not permit continuing
aspirin and clopidogrel throughout the perioperative period, we
suggest a DES not be used (although it is possible that a
sirolimus-eluting stent might be safe in this setting); we recom-
mend a non-DES stent, perhaps one that might possibly reduce
thrombosis without clopidogrel on-board during the pro-
thrombotic state of surgery, such as a heparin-coated or
phosphorylcholine-coated stent (though it must be emphasized
that it is entirely unproven that such stents do indeed reduce stent
thrombosis in humans, let alone following noncardiac surgery). It
is also possible that balloon angioplasty alone is a reasonable option
for certain lesion types and clinical situations prior to noncardiac
surgery if a satisfactory result can be achieved.
We also thank Dr. Mendoza and colleagues for their interest in
our study. We agree that our investigation was severely limited in
its ability to detect the relationship between the concomitant
antiplatelet therapy administered following preoperative PCI, time
to surgery, and perioperative bleeding; undoubtedly such a rela-
tionship exists. Our study does not, however, demonstrate, or even
address, whether preoperative PCI increases adverse perioperative
cardiac events. Preoperative PCI was performed in most patients
included in our study in an attempt to reduce such events, although
we agree that data are lacking whether it actually does so. We
support the call by Mendoza and colleagues for large prospective
studies of this issue; fortunately, several are underway. In the
meantime, the choice of either stent (bare metal vs. drug eluting)
or reliance on balloon angioplasty without stent placement is an
important consideration for the interventionalist performing revas-
cularization on high-risk patients who might possibly benefit from
revascularization before undergoing high-risk surgery. We are of
the opinion, however, that most patients with coronary disease in
whom noncardiac surgery is planned do not require preoperative
revascularization. In general, the indications for revascularization
before noncardiac surgery are the same as in patients in whom
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surgery is not planned, and it is rare to need to revascularize a
patient just “to get them through surgery.”
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